Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05852769 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT05852769 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 18 participants.
The verdict
NCT05852769, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study is designed to assess the effect of BMS-986196 on the drug levels of caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin in healthy participants.
Interventions
- DRUG Montelukast
- DRUG Omeprazole
- DRUG Caffeine
- DRUG Flurbiprofen
- DRUG BMS-986196
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2023-08-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05852769
The ClinicalTrials.gov registry entry for NCT05852769 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Montelukast is the first listed.
NCT05852769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05852769 about?
NCT05852769 is a clinical study titled "A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants". This study is designed to assess the effect of BMS-986196 on the drug levels of caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin in healthy participants.
What is the current status of trial NCT05852769?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-05-31. Estimated completion is 2023-08-24.
What interventions are being tested in trial NCT05852769?
The interventions under investigation include: Montelukast (DRUG), Omeprazole (DRUG), Caffeine (DRUG), Flurbiprofen (DRUG), BMS-986196 (DRUG).
Who is sponsoring clinical trial NCT05852769?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.